CARVYKTI®治疗效果 - CARVYKTI®在1-3种先前治疗线路中降低疾病进展或死亡风险59%[1] - CARVYKTI®在早期治疗复发/难治性多发性骨髓瘤中表现出显著的疗效[2] - CARVYKTI®是一种通过利用患者的免疫系统或T细胞来对抗疾病的细胞疗法[3] CARVYKTI®神经毒性 - CARVYKTI®治疗后可能出现严重的神经毒性[24] - 在CARTITUDE-1 & 4研究中，24%的患者出现了一种或多种神经毒性，其中7%为严重病例[25] - 神经毒性的类型包括ICANS、帕金森症状、GBS、免疫介导的脊髓炎、周围神经病变和颅神经麻痹[26] CARVYKTI®过敏反应和二次恶性肿瘤 - CARVYKTI®可能导致严重过敏反应，包括过敏性休克，应在输注后仔细监测患者2小时以观察严重反应的迹象和症状[60] - CARVYKTI®治疗的患者可能发展出二次恶性肿瘤，其中在接受CARVYKTI®治疗的患者中，有5%（13/285）的患者出现髓样肿瘤（9例骨髓增生异常综合征，3例急性髓样白血病，1例骨髓增生异常综合征后发展为急性髓样白血病）[61] CARVYKTI®神经事件风险 - 由于CARVYKTI®可能导致神经事件，包括精神状态改变，癫痫发作，神经认知下降或神经病，接受CARVYKTI®治疗的患者在CARVYKTI®输注后的8周内有意识或协调能力下降的风险[63]

News of healthcare behemoth Johnson & Johnson (JNJ)  acquiring medical device company ShockWave Medical (SWAV)  made headlines this morning. The acquisition is expected to be completed later this year and is valued at $13.1 billion or $335 a share and 3% above ShockWave's current stock price. ShockWave’s stock is up 2% in Friday’s trading session with Johnson & Johnson shares virtually flat and trading at $152 a share. With that being said, let’s see if it’s a good time to buy stock in either of these healt ...

强生公司收购Shockwave Medical - 强生公司宣布以131亿美元收购心血管导管制造商Shockwave Medical，提高其心脏治疗产品组合[1] - 收购价格为每股335美元，比昨日Shockwave的收盘价溢价4.7%[1] - 强生公司表示，此次收购增强了其在快速增长的心血管介入市场的实力[1] - 强生公司表示，此次收购将使其心血管产品组合得到增强，之前还收购了Abiomed和Laminar[4] - 强生公司将通过现金和债务来融资这笔交易，预计交易将在年中前完成，需获得Shockwave投资者的批准[6]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Shockwave Medical Inc (NASDAQ:SWAV) is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson (JNJ) announced it would buy the company for $12.5 billion, boosting its portfolio of cardiovascular disease treatment devices. SWAV was last seen up 1.8% at $325.77 after the news, while JNJ is down 0.07% at $152.38.SWAV received a pair of bear notes in response. Needham downgraded the stock to "hold" from "buy," while Piper Sandler slashed its rating to "neutral" from "overweight." Of the ...

强生公司收购Shockwave Medical公司 - 强生公司将以131亿美元的价格收购Shockwave Medical公司，扩大心血管干预领域的业务[1] - 强生公司表示，此次收购将增强其治疗两种常见心脏疾病的产品组合[2] - 强生公司将以每股335美元的现金支付Shockwave公司，后者是一家生产基于导管的治疗方案的制造商，用于治疗动脉堵塞的患者[3]

Johnson & Johnson (NYSE:JNJ) is buying medical device company Shockwave Medical (NASDAQ:SWAV) for $13.1 billion. Shockwave makes devices that perform Intravascular Lithotripsy. They break up calcium deposits in arteries with sound waves, in the same way kidney stones have been treated for 30 years. The announcement had limited impact on the stock, however. SWAV stock was set to open this morning at about $325 per share, up just 1.6% from its April 4 close. JNJ stock was nearly unchanged at $153.Why No Big S ...

强生公司收购Shockwave Medical公司 - 强生公司宣布以131亿美元收购Shockwave Medical公司[1] - Shockwave Medical股价上涨至335美元，而强生公司股价也略有上涨[1] - Shockwave Medical股价在2024年4月4日上涨了68%，达到319.99美元，市场猜测可能会被收购，而强生公司股价下跌了2.7%[3] - 强生公司表示这笔交易将增强其在心血管干预领域的地位，并加速其向高增长市场的转变。预计这笔全现金交易将在2024年中期完成，待获得监管批准[5] Shockwave Medical公司业务 - Shockwave Medical是血管内碎石术的领导者，这是一种破解血管壁中硬化钙质的方法[4]

Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion.Shockwave Medical stock priced at a premium Copy link to section The all-cash agreement values each share of Shockwave Medical at $335 – a 5.0% premium on their previous close. JNJ expects the acquisition to help it further expand its footprint in cardiovascular interventions. Joaquin Duato – its chief executive said in a press release today:Shockwave and ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Johnson & Johnson (JNJ) , which belongs to the Zacks Large Cap Pharmaceuticals industry, could be a great candidate to consider.When looking at the last two reports, this world's biggest maker of health care products has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 3.22%, on average, in the last two qua ...